SEATTLE, Wash. – Nov. 7, 2025 – The number of adults living with chronic kidney disease (CKD) has more than doubled since 1990, reaching nearly 800 million worldwide, according to new research published in The Lancet. The findings come from the Global Burden of Disease (GBD) 2023 study, which tracked CKD trends among adults age 20 years and older across 204 countries and territories from 1990 through 2023.

About The Study: The findings of this study support the routine use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve kidney outcomes across the full spectrum of kidney function and albuminuria among patients with type 2 diabetes, chronic kidney disease, or heart failure. 

A recent analysis of 2,915 patients with primary glomerular diseases indicatesthat young patients may face similar risks of kidney function decline as older patients, indicating that they are more likely to need dialysis or a kidney transplant during their lifetimes.

The findings will be presented at American Society of Nephrology (ASN)Kidney Week 2025 November 5–9.

Dual inhibition of sodium-glucose co-transporters 1 and 2 with the recently approved drug sotagliflozin may be an especially effectivetreatment for salt- sensitive hypertension.

The findings will be presented at American Society of Nephrology (ASN)Kidney Week 2025 November 5–9.

Nearly all SPRINT participants with hypertension and nondiabetic chronickidney disease stages 3–4 had a net benefit (the predicted difference between benefits and harms) that favored a systolic blood pressure target of <120 mm Hg compared with <140 mm Hg.

The findings will be presented at American Society of Nephrology (ASNKidney Week 2025 November 5–9.

Monica Verduzco-Gutierrez, MD, a physiatrist with UT Health San Antonio, the academic health center of The University of Texas at San Antonio, helped craft new guidelines on treating traumatic brain injuries as part of a natiional clinical practice working group.

About The Study: In the Chronic Kidney Disease Prognosis Consortium, 11% of outpatient participants and 35% of hospitalized patients had a cystatin C–based estimated glomerular filtration rate (eGFRcys) that was at least 30% lower than their creatinine-based eGFR (eGFRcr). In the outpatient setting, presence of eGFRcys at least 30% lower than eGFRcr was associated with significantly higher rates of all-cause mortality, cardiovascular events, and kidney failure.